Miraca to Promote MDxHealth's Prostate Cancer Test | GenomeWeb

NEW YORK (GenomeWeb) – MDxHealth today announced a deal with Miraca Life Sciences to promote MDxHealth's ConfirmMDx Prostate Cancer test.

"Through this strategic partnership with MDxHealth, we can now offer a well-validated epigenetic assay, which delivers new molecular insights on a patient's risk for undetected cancer, thereby enabling our clients make more informed decisions about the need for a repeat prostate biopsy," Miraca President and CEO Frank Basile said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.